Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease

Area of Science:

• Pulmonology
• Genetics
• Internal Medicine

Background:

• Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder leading to reduced alpha-1 antitrypsin (AAT) levels or function.
• This deficiency results in unchecked neutrophil elastase activity, causing progressive lung tissue destruction and contributing to Chronic Obstructive Pulmonary Disease (COPD).
• AATD-related COPD is often underdiagnosed despite guidelines recommending systematic evaluation, particularly in high-risk patients.

Purpose of the Study:

• To review current evidence on AATD-associated COPD.
• To focus on genetic basis, pathophysiological features, clinical heterogeneity, diagnostic approaches, and management.
• To highlight the importance of personalized management strategies integrating genotype and disease behavior.

Main Methods:

• Narrative review of current evidence.
• Analysis of genetic basis and pathophysiological features.
• Evaluation of clinical and functional heterogeneity, diagnostic and monitoring approaches, and management considerations.

Main Results:

• AATD-related COPD presents with diverse pathological and clinical features beyond typical emphysema, including early onset and extrapulmonary manifestations.
• Diagnosis is challenged by discordance between airflow limitation and gas transfer, and early small airway involvement, necessitating multimodal assessment.
• Current management follows COPD principles, with AAT augmentation therapy as the only disease-modifying option for selected patients.

Conclusions:

• AATD-related COPD requires a multimodal diagnostic approach and personalized management strategies.
• Emerging therapies underscore the need to integrate genetic information and longitudinal disease behavior for optimal patient care.
• Increased awareness and systematic screening are vital for improving diagnosis and outcomes in AATD-associated COPD.